These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 22494747)

  • 1. Re: low-intensity extracorporeal shock wave therapy--a novel effective treatment for erectile dysfunction in severe ED patients who respond poorly to PDE5 inhibitor therapy.
    Seftel AD
    J Urol; 2012 May; 187(5):1789-90. PubMed ID: 22494747
    [No Abstract]   [Full Text] [Related]  

  • 2. Does low intensity extracorporeal shock wave therapy have a physiological effect on erectile function? Short-term results of a randomized, double-blind, sham controlled study.
    Vardi Y; Appel B; Kilchevsky A; Gruenwald I
    J Urol; 2012 May; 187(5):1769-75. PubMed ID: 22425129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie's disease and erectile dysfunction: results from a prospective randomized trial.
    Palmieri A; Imbimbo C; Creta M; Verze P; Fusco F; Mirone V
    Int J Androl; 2012 Apr; 35(2):190-5. PubMed ID: 22085227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphodiesterase type 5 inhibitor therapy: identifying and exploring what attributes matter more to clinicians and patients in the management of erectile dysfunction.
    Axilrod AC
    Curr Med Res Opin; 2007 Dec; 23(12):3189-98. PubMed ID: 17991309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The evolving role of testosterone in the treatment of erectile dysfunction.
    Shabsigh R; Rajfer J; Aversa A; Traish AM; Yassin A; Kalinchenko SY; Buvat J
    Int J Clin Pract; 2006 Sep; 60(9):1087-92. PubMed ID: 16939550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study.
    Hatzichristou D; Haro JM; Martin-Morales A; von Keitz A; Riley A; Bertsch J; Belger M; Wolka AM; Beardsworth A;
    Int J Clin Pract; 2007 Nov; 61(11):1850-62. PubMed ID: 17850306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of avanafil for treating erectile dysfunction: results of a multicentre, randomized, double-blind, placebo-controlled trial.
    Zhao C; Kim SW; Yang DY; Kim JJ; Park NC; Lee SW; Paick JS; Ahn TY; Moon KH; Chung WS; Min KS; Suh JK; Hyun JS; Park K; Park JK
    BJU Int; 2012 Dec; 110(11):1801-6. PubMed ID: 22448738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Gene therapy for erectile dysfunction: an update].
    Liu JH; Li MC
    Zhonghua Nan Ke Xue; 2011 Feb; 17(2):99-103. PubMed ID: 21404703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of PDE5 inhibition combined with free oxygen radical scavenger therapy on erectile function in a diabetic animal model.
    De Young L; Yu D; Freeman D; Brock GB
    Int J Impot Res; 2003 Oct; 15(5):347-54. PubMed ID: 14562136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PDE5 inhibitors: are there differences?
    Carson CC
    Can J Urol; 2006 Feb; 13 Suppl 1():34-9. PubMed ID: 16526979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining testosterone and PDE5 inhibitors in erectile dysfunction: basic rationale and clinical evidences.
    Greco EA; Spera G; Aversa A
    Eur Urol; 2006 Nov; 50(5):940-7. PubMed ID: 16979814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erectile dysfunction: evaluation and new treatment options.
    Carson CC
    Psychosom Med; 2004; 66(5):664-71. PubMed ID: 15385689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erectile dysfunction: anatomical parameters, etiology, diagnosis, and therapy.
    Hafez ES; Hafez SD
    Arch Androl; 2005; 51(1):15-31. PubMed ID: 15764414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Duration of erectile dysfunction and its relationship to treatment seeking and satisfaction with treatment using PDE5 inhibitors.
    Matic H; McCabe MP
    Int J Urol; 2008 Apr; 15(4):346-9. PubMed ID: 18380826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evaluation of ambulatory cardiac rehabilitation influence on the intensity of erectile dysfunction in patients with ischemic heart disease].
    Kałka D; Sobieszczańska M; Pilecki W; Szawrowicz-Pełka T; Marciniak W; Sebzda T; Turbański J; Palczewska V; Adamus J
    Pol Merkur Lekarski; 2009 Oct; 27(160):290-5. PubMed ID: 19928656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erectile dysfunction and coronary artery disease prediction: evidence-based guidance and consensus.
    Jackson G; Boon N; Eardley I; Kirby M; Dean J; Hackett G; Montorsi P; Montorsi F; Vlachopoulos C; Kloner R; Sharlip I; Miner M
    Int J Clin Pract; 2010 Jun; 64(7):848-57. PubMed ID: 20584218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene therapy and erectile dysfunction: the current status.
    Lau DH; Kommu SS; Siddiqui EJ; Thompson CS; Morgan RJ; Mikhailidis DP; Mumtaz FH
    Asian J Androl; 2007 Jan; 9(1):8-15. PubMed ID: 16888683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors that predict changing the type of phosphodiesterase type 5 inhibitor medication among men in the UK.
    Kell PD; Hvidsten K; Morant SV; Harnett JP; Bridge S
    BJU Int; 2007 Apr; 99(4):860-3. PubMed ID: 17378846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erectile dysfunction and hypertension.
    Kloner R
    Int J Impot Res; 2007; 19(3):296-302. PubMed ID: 17151696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Centrally acting mechanisms for the treatment of male sexual dysfunction.
    Miner MM; Seftel AD
    Urol Clin North Am; 2007 Nov; 34(4):483-96, v. PubMed ID: 17983889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.